Abstract
Transformation and cancer growth are regulated by the coordinate actions of oncogenes and tumor suppressors. Here, we show that the novel E3 ubiquitin ligase HACE1 is frequently downregulated in human tumors and maps to a region of chromosome 6q21 implicated in multiple human cancers. Genetic inactivation of HACE1 in mice results in the development of spontaneous, late-onset cancer. A second hit from either environmental triggers or genetic heterozygosity of another tumor suppressor, p53, markedly increased tumor incidence in a Hace1-deficient background. Re-expression of HACE1 in human tumor cells directly abrogates in vitro and in vivo tumor growth, whereas downregulation of HACE1 via siRNA allows non-tumorigenic human cells to form tumors in vivo. Mechanistically, the tumor-suppressor function of HACE1 is dependent on its E3 ligase activity and HACE1 controls adhesion-dependent growth and cell cycle progression during cell stress through degradation of cyclin D1. Thus, HACE1 is a candidate chromosome 6q21 tumor-suppressor gene involved in multiple cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thiagalingam, S. et al. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14, 65–72 (2002).
Hyytinen, E.R. et al. Defining the region(s) of deletion at 6q16–q22 in human prostate cancer. Genes Chromosom. Cancer 34, 306–312 (2002).
Inoue, M. et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am. J. Pathol. 161, 1507–1513 (2002).
Orphanos, V. et al. Allelic imbalance of chromosome 6q in ovarian tumors. Br. J. Cancer 71, 666–669 (1995).
Utada, Y. et al. Mapping of target regions of allelic loss in primary breast cancers to 1-cM intervals on genomic contigs at 6q21 and 6q25.3. Jpn. J. Cancer Res. 91, 293–300 (2000).
Zhang, Y. et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosom. Cancer 27, 52–58 (2000).
Morelli, C. et al. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 21, 7266–7276 (2002).
Fernandez, C.V., Lestou, V.S., Wildish, J., Lee, C.L. & Sorensen, P.H. Detection of a novel t(6;15)(q21;q21) in a pediatric Wilms' tumor. Cancer Genet. Cytogenet. 129, 165–167 (2001).
Solis, V., Pritchard, J. & Cowell, J.K. Cytogenetic changes in Wilms' tumors. Cancer Genet. Cytogenet. 34, 223–234 (1988).
Hoban, P.R. et al. Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumor. J. Med. Genet. 34, 343–345 (1997).
Bruce, C.K., Howard, P., Nowak, N.J. & Hoban, P.R. Molecular analysis of region t(5;6)(q21;q21) in Wilms tumor. Cancer Genet. Cytogenet. 141, 106–113 (2003).
Anglesio, M.S. et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum. Mol. Genet. 13, 2061–2074 (2004).
Huibregtse, J.M., Scheffner, M., Beaudenon, S. & Howley, P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 92, 2563–2567 (1995).
Jones, P.A. & Baylin, S.B. The epigenomics of cancer. Cell 128, 683–692 (2007).
Sharpless, N.E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86–91 (2001).
Sharpless, N.E. et al. p16INK4a and p53 deficiency cooperate in tumorigenesis. Cancer Res. 62, 2761–2765 (2002).
Herzog, C.R., Noh, S., Lantry, L.E., Guan, K.L. & You, M. Cdkn2a encodes functional variation of p16INK4a but not p14ARF, which confers selection in mouse lung tumorigenesis. Mol. Carcinog. 25, 92–98 (1999).
Jackson, R.J. et al. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 21, 8486–8497 (2002).
Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215–221 (1992).
Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5, 225–229 (1993).
Fogh, J., Fogh, J.M. & Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59, 221–226 (1977).
Lovvorn, H.N., III, Savani, R.C., Ruchelli, E., Cass, D.L. & Adzick, N.S. Serum hyaluronan and its association with unfavorable histology and aggressiveness of heterotransplanted Wilms' tumor. J. Pediatr. Surg. 35, 1070–1078 (2000).
Bagui, T.K., Mohapatra, S., Haura, E. & Pledger, W.J. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol. Cell. Biol. 23, 7285–7290 (2003).
Diehl, J.A., Cheng, M., Roussel, M.F. & Sherr, C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499–3511 (1998).
Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222–231 (2001).
Jones, P.A. & Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415–428 (2002).
Diehl, J.A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 1, 226–231 (2002).
Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477–491 (2004).
Bock, C. et al. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21, 4067–4068 (2005).
Tognon, C.E. et al. Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol. Cell. Biol. 18, 6995–7008 (1998).
Tognon, C. et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367–376 (2002).
Thomas, N.A., Neville, P.J., Baxter, S.W. & Campbell, I.G. Genetic analysis of benign ovarian tumors. Int. J. Cancer 105, 499–505 (2003).
Gaidano, G. et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80, 1781–1787 (1992).
Takeuchi, S. et al. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 22, 6970–6976 (2003).
Li, B.C. et al. Allelic loss of chromosome 6q in gastric carcinoma. Diagn. Mol. Pathol. 12, 193–200 (2003).
Yoon, J. & Ko, Y.H. Deletion mapping of the long arm of chromosome 6 in peripheral T and NK cell lymphomas. Leuk. Lymphoma 44, 2077–2082 (2003).
Fujii, H., Zhou, W. & Gabrielson, E. Detection of frequent allelic loss of 6q23-q25.2 in microdissected human breast cancer tissues. Genes Chromosom. Cancer 16, 35–39 (1996).
Fujii, S., Takeshima, Y., Arihiro, K., Kaneko, M. & Inai, K. Microsatellite instability in breast cancers with special reference to patients' age and bilaterality. Hiroshima J. Med. Sci. 47, 89–97 (1998).
Fujii, H. et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res. Treat. 76, 255–260 (2002).
Trink, B. et al. Absence of TSG101 transcript abnormalities in human cancers. Oncogene 16, 2815–2818 (1998).
Smeds, J. et al. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumor events: analysis of loss of heterozygosity. Acta Oncol. 44, 41–49 (2005).
Yatsuoka, T. et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am. J. Gastroenterol. 95, 2080–2085 (2000).
Konishi, N. et al. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci. 94, 764–768 (2003).
Nakamura, M. et al. Novel tumor suppressor loci on 6q22–23 in primary central nervous system lymphomas. Cancer Res. 63, 737–741 (2003).
Barghorn, A. et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am. J. Pathol. 158, 1903–1911 (2001).
Acknowledgements
We thank P. Grundy and the Children's Oncology Group as well as the Cooperative Human Tissue Network (CHTN) for providing clinical Wilms' tumor samples for this study; A. Brooks-Wilson and M. Marra for HACE1 sequencing assistance; R. Kandel and D. Holmyard for help with electron microscopy of the sarcoma samples; D. Bouchard and N.-J. Chen for assistance with FACS, M. Bowden and M. Gleave for assistance with nude mouse studies; and V. Evdokimova, T. Zoranovic, K. Kuba, N. Joza, A. Oliveira-dos Santos, M. Crackower, I. Kozieradski, T. Nakashima, H. Jones Taggart, M. Cheung, M. Rangachari, Y. Liu, M. Sun and M. Pollard for discussions, technical help and reagents. The GFP-tagged activated Ki-Ras plasmid was provided by R. Kay, Terry Fox Laboratory, British Columbia Cancer Research Centre. This work was supported by the National Cancer Institute of Canada (NCIC) (to P.H.S.), a Canadian Institutes of Health Research (CIHR) post-doctoral fellowship (to F.Z.), the Institute for Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), the Jubilaeumsfonds of the Austrian National Bank, GEN-AU and an EU Excellence grant to J.M.P.
Author information
Authors and Affiliations
Contributions
L.Z. made Hace1 mutant mice in the laboratory of J.M.P. and later in the laboratory of P.P.L. and analyzed the tumors in vivo with significant help from G.Y., R.S., M.P.N., S.C., H.H., T.W. and P.P.L. M.S.A. performed most of the in vitro cell line experiments, with significant assistance from F.Z., N.M. and L.L. M.O. and P.H.S. are trained pathologists and assessed the tumors histologically. J.F. and R.J.A. did all methylation studies reported in the paper. P.H.S. and J.M.P. supervised and initiated the project from the outset and together wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
One coauthor, P.S., has applied for a U.S. patent on the HACE1 protein.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figs. 1–12, Supplementary Table 1 and Supplementary References (PDF 10572 kb)
Rights and permissions
About this article
Cite this article
Zhang, L., Anglesio, M., O'Sullivan, M. et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med 13, 1060–1069 (2007). https://doi.org/10.1038/nm1621
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1621
This article is cited by
-
Optineurin links Hace1-dependent Rac ubiquitylation to integrin-mediated mechanotransduction to control bacterial invasion and cell division
Nature Communications (2022)
-
HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells
Signal Transduction and Targeted Therapy (2021)
-
HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner
Oncogene (2021)
-
HACE1 is a potential tumor suppressor in osteosarcoma
Cell Death & Disease (2019)
-
Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells
Oncogene (2019)